AMNEAL PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $4.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2026-06-30 was $8.57M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2026-03-31 was -$4.30M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2025-12-31 was -$7.79M, a 152.42% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2025-09-30 was -$12.61M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2025 was -$46.45M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2024 was -$6.96M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2023 was -$39.68M, a 213.78% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $34.88M, a 108.63% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.28M 10-Q · filed 2026-08-06 | -$3.51M derived: sum of 3 quarters · filed 2026-08-06 | -$16.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.30M 10-Q · filed 2026-05-07 | -$12.09M derived: sum of 2 quarters · filed 2026-05-07 | -$24.70M derived: sum of 3 quarters · filed 2026-05-07 | -$36.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$7.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$20.40M derived: sum of 2 quarters · filed 2026-02-27 | -$32.66M derived: sum of 3 quarters · filed 2026-08-06 | -$46.45M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$12.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$24.87M derived: sum of 2 quarters · filed 2026-08-06 | -$38.66M 10-Q · filed 2025-11-06 | -$23.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$12.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$26.05M 10-Q · filed 2026-08-06 | -$11.19M derived: sum of 3 quarters · filed 2026-08-06 | -$47.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.79M 10-Q · filed 2026-05-07 | $1.07M derived: sum of 2 quarters · filed 2026-05-07 | -$35.69M derived: sum of 3 quarters · filed 2026-05-07 | -$35.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$21.90M derived: sum of 2 quarters · filed 2026-02-27 | -$22.11M derived: sum of 3 quarters · filed 2026-02-27 | -$6.96M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$36.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$36.97M derived: sum of 2 quarters · filed 2025-11-06 | -$21.82M 10-Q · filed 2025-11-06 | -$55.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $14.94M 10-Q · filed 2025-08-07 | -$18.59M derived: sum of 3 quarters · filed 2025-08-07 | -$22.81M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $15.15M 10-Q · filed 2025-05-07 | -$18.38M derived: sum of 2 quarters · filed 2025-05-07 | -$22.60M derived: sum of 3 quarters · filed 2025-05-07 | -$18.29M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$33.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$37.75M derived: sum of 2 quarters · filed 2025-02-28 | -$33.44M derived: sum of 3 quarters · filed 2025-02-28 | -$39.68M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$4.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $91.00K derived: sum of 2 quarters · filed 2023-11-09 | -$6.15M 10-Q · filed 2023-11-09 | -$8.75M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-06-30 | $4.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.93M 10-Q · filed 2023-08-08 | -$4.53M derived: sum of 3 quarters · filed 2024-03-14 | $7.14M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | -$6.24M 10-Q · filed 2023-05-09 | -$8.84M derived: sum of 2 quarters · filed 2024-03-14 | $2.83M derived: sum of 3 quarters · filed 2024-03-14 | $4.05M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $9.07M derived: sum of 2 quarters · filed 2024-03-14 | $10.29M derived: sum of 3 quarters · filed 2024-03-14 | $34.88M 10-K · filed 2024-03-14 |
| 2022-09-30 | $11.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $12.89M derived: sum of 2 quarters · filed 2022-11-07 | $37.48M 10-Q · filed 2022-11-07 | $45.89M derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $25.81M 10-Q · filed 2022-08-08 | $34.22M derived: sum of 3 quarters · filed 2023-03-03 | $34.98M derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-03-31 | $24.59M 10-Q · filed 2022-05-06 | $33.00M derived: sum of 2 quarters · filed 2023-03-03 | $33.77M derived: sum of 3 quarters · filed 2023-03-03 | $34.20M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $9.18M derived: sum of 2 quarters · filed 2023-03-03 | $9.61M derived: sum of 3 quarters · filed 2023-03-03 | $16.72M 10-K · filed 2023-03-03 |
| 2021-09-30 | $766.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.20M derived: sum of 2 quarters · filed 2021-11-08 | $8.31M 10-Q · filed 2021-11-08 | $8.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | $438.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $7.54M 10-Q · filed 2021-08-09 | $7.54M derived: sum of 3 quarters · filed 2022-03-01 | $5.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $7.10M 10-Q · filed 2021-05-07 | $7.11M derived: sum of 2 quarters · filed 2022-03-01 | $5.51M derived: sum of 3 quarters · filed 2022-03-01 | -$762.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$1.60M derived: sum of 2 quarters · filed 2022-03-01 | -$7.87M derived: sum of 3 quarters · filed 2022-03-01 | -$41.20M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$7.87M derived: sum of 2 quarters · filed 2020-11-06 | -$41.20M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$6.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$39.61M 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | -$33.34M 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $7.04M 10-K · filed 2021-03-01 | |||
| 2018-12-31 | -$696.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |